Latest news with #BrightSpringHealthServices
Yahoo
06-08-2025
- Business
- Yahoo
3 Growth Stocks with Explosive Upside
Growth boosts valuation multiples, but it doesn't always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022. The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. Keeping that in mind, here are three growth stocks expanding their competitive advantages. Braze (BRZE) One-Year Revenue Growth: +22.7% Founded in 2011 after the co-founders met at NYC Disrupt Hackathon, Braze (NASDAQ:BRZE) is a customer engagement software platform that allows brands to connect with customers through data-driven and contextual marketing campaigns. Why Could BRZE Be a Winner? Ability to secure long-term commitments with customers is evident in its 23.1% ARR growth over the last year Forecasted revenue growth of 18.5% for the next 12 months indicates its momentum over the last three years is sustainable Operating margin improvement of 8.5 percentage points over the last year demonstrates its ability to scale efficiently Braze is trading at $27.02 per share, or 3.8x forward price-to-sales. Is now a good time to buy? See for yourself in our in-depth research report, it's free. BrightSpring Health Services (BTSG) One-Year Revenue Growth: +28.1% Founded in 1974, BrightSpring Health Services (NASDAQ:BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services. Why Does BTSG Stand Out? Annual revenue growth of 21.3% over the last two years was superb and indicates its market share increased during this cycle Sales outlook for the upcoming 12 months implies the business will stay on its desirable two-year growth trajectory Earnings growth has trumped its peers over the last four years as its EPS has compounded at 26.3% annually At $20.84 per share, BrightSpring Health Services trades at 20.2x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. German American Bancorp (GABC) One-Year Revenue Growth: +19.9% Founded in 1910 during a wave of community banking expansion in the Midwest, German American Bancorp (NASDAQ:GABC) is a financial holding company that provides banking, wealth management, and insurance services across southern Indiana and Kentucky. Why Do We Like GABC? Annual net interest income growth of 13.3% over the last five years was superb and indicates its market share increased during this cycle Demand for the next 12 months is expected to accelerate above its five-year trend as Wall Street forecasts robust net interest income growth of 26.9% Projected tangible book value per share growth of 16.7% for the next 12 months is above its two-year trend, pointing to accelerating profitability German American Bancorp's stock price of $38.41 implies a valuation ratio of 1.3x forward P/B. Is now the time to initiate a position? See for yourself in our full research report, it's free. High-Quality Stocks for All Market Conditions Donald Trump's April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don't miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
05-08-2025
- Business
- Yahoo
The Pennant Group (PNTG) To Report Earnings Tomorrow: Here Is What To Expect
Senior living provider The Pennant Group (NASDAQ:PNTG) will be reporting results this Wednesday after market close. Here's what investors should know. The Pennant Group beat analysts' revenue expectations by 4.1% last quarter, reporting revenues of $209.8 million, up 33.7% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' EPS estimates and a narrow beat of analysts' sales volume estimates. Is The Pennant Group a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting The Pennant Group's revenue to grow 24.9% year on year to $210.7 million, slowing from the 27.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.27 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. The Pennant Group has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 5% on average. Looking at The Pennant Group's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. BrightSpring Health Services traded down 6.1% following the results while Option Care Health was also down 2.7%. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. The Pennant Group is down 11.3% during the same time and is heading into earnings with an average analyst price target of $33.60 (compared to the current share price of $22.94). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
03-08-2025
- Business
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-08-2025
- Business
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-08-2025
- Business
- Yahoo
BrightSpring Health Services Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BrightSpring Health Services (NASDAQ:BTSG) Second Quarter 2025 Results Key Financial Results Revenue: US$3.15b (up 15% from 2Q 2024). Net income: US$9.21m (down 54% from 2Q 2024). Profit margin: 0.3% (down from 0.7% in 2Q 2024). EPS: US$0.046 (down from US$0.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period BrightSpring Health Services Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates by 9.3%. Looking ahead, revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 4.3% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for BrightSpring Health Services (of which 1 is a bit unpleasant!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
